There are over 7000 rare genetic disorders (RGD) and only 5% of them have FDA approved treatments. Though the number of RGDs is high, they are heterogenous and geographically disparate…. CONTINUE
Application of Natural Language Processing in Clinical Applications
Natural Language Processing is a field of computational linguistics, computer science and more specially artificial intelligence (AI) that uses statistics, machine learning (ML) and deep learning (DL) techniques to understand… CONTINUE
Massachusetts Startup Wins Horizon Prize, Powered by MIT Solve, with Algorithm-Based FindEHR Solution for Finding Undiagnosed Genetic Disorder Patients using Electronic Medical Records
ThinkGenetic combines modern machine learning with practical information in genetics to solve a major concern in healthcare – the identification of patients living with undiagnosed rare genetic conditions Boston, MA,… CONTINUE
Ochsner Lafayette Healthcare Innovation Fund Invests in ThinkGenetic Vision for Genetic Disease Identification in Local Patients
LAFAYETTE, La., April 20, 2021 (Newswire.com) – Today ThinkGenetic, Inc. (thinkgenetic.com) announces the official acceptance of a $500,000 investment from the Ochsner Lafayette General Healthcare Innovation Fund. “After years of working… CONTINUE
From Friend to Intern to Advocate: A Reflection on My Experience with Duchenne Muscular Dystrophy
Editor’s Note: Today I am excited to release this article, written by an incredible young woman I’ve grown to know and respect as our Digital Marketing Intern. Courtney Burt’s time… CONTINUE
ThinkGenetic Declared a PULSE@MassChallenge Top Digital Health Startup
In a recent press release, PULSE@MassChallenge announced that ThinkGenetic was accepted into the Boston-based 2018 startup class out of 500 worldwide applicants. Previous startups that have participated in PULSE@MassChallenge have… CONTINUE
ThinkGenetic to Engage with Rare Disease Community at Global Genes’ 6th Annual RARE Patient Advocacy Summit
ThinkGenetic, Inc. is delighted to be participating in the 6th Annual RARE Patient Advocacy Summit and Partnering and Investor Forum to further its mission of empowering the rare disease community… CONTINUE